Andreu Òdena

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Venues

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Vall d´Hebron Institut d´Oncologia

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vall d´Hebron Institut d´Oncologia Jun 20 2019 - Feb 24 2020

Spain

Undergraduate Student researcher :: Experimental Therapeutic Group

Publications

Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Fara Brasó-Maristany, Juan Manuel Ferrero-Cafiero, Claudette Falato, Adrienne G Waks, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador-Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Andreu Òdena, Violeta Serra, Francisco J Pardo-Palacios, Ana María Luna Barrera, Miriam Arumi, Juan Antonio Guerra, Guillermo Villacampa, Rodrigo Sánchez-Bayona, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzugaza, Patricia Galván, Judith Matito, Sonia Pernas, María Jesús Vidal Losada, Anu Santhanagopal, Dalila Sellami, Stephen Esker, Pang-Dian Fan, Fumitaka Suto, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response. Nature communications 15 (1) (2024)
Albert Gris-Oliver, Marta Palafox, Laia Monserrat, Fara Brasó-Maristany, Andreu Òdena, Mònica Sánchez-Guixé, Yasir H Ibrahim, Guillermo Villacampa, Judit Grueso, Mireia Parés, Marta Guzmán, Olga Rodríguez, Alejandra Bruna, Caroline S Hirst, Alan Barnicle, Elza C de Bruin, Avinash Reddy, Gaia Schiavon, Joaquín Arribas, Gordon B Mills, Carlos Caldas, Rodrigo Dienstmann, Aleix Prat, Paolo G Nuciforo, Pedram Razavi, Maurizio Scaltriti, Nicholas C Turner, Cristina Saura, Barry R Davies, Mafalda Oliveira, Violeta Serra
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (14) (2020)

Andreu Òdena.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Andreu Òdena